Key points from article :
Genomic sequencing is increasingly used to match cancer patients to clinical trials of targeted drugs.
Test focuses on detecting defects in tumour cell DNA repair mechanisms.
Test looks for genomic errors in cancer cells, make them sensitive to some specialised drugs.
Researchers used 110 tumour samples from men with metastatic ‘castration-resistant’ prostate cancer.
Researchers were able to match prostate cancer patients to a trial of olaparib.
Targeted drugs react specifically with cancer cells, cause fewer side effects than chemotherapy.
Study was published in Clinical Cancer Research.
Research was led by scientists from The Institute of Cancer Research, London.
